Figure 4.
Overview of STAT3 activation via the JAK-STAT pathway (cytokine and growth factor receptor stimulation) and cytoplasmic Src kinase. A JAK inhibitor (ruxolitinib), STAT3 inhibitors (danvatirsen, napabucasin) and a Src inhibitor (dasatinib) are currently in clinical trials for pancreatic cancer.
